Synthetix Proposes $27 Million Acquisition of Derive to Integrate Derivatives Ecosystem
On May 14, the decentralized finance protocol Synthetix proposed an acquisition of the decentralized options platform Derive (formerly known as Lyra), with a total transaction value of approximately $27 million. According to the SIP-415 proposal, Synthetix will issue up to 29.3 million SNX tokens at a ratio of 27:1 (3-month lock-up, 9-month linear release) in exchange for Derive's DRV tokens.
This acquisition requires approval from Synthetix's Spartan Council and Derive's governance body. If the transaction is completed, Synthetix will integrate Derive's order book perpetual contract trading technology and development team, further accelerating the construction of the Ethereum mainnet derivatives protocol. Derive's modular order book design and options mechanism experience will directly enhance Synthetix's core competitiveness, and its developed App-chain technology stack can be immediately deployed to the mainnet.
This will be Synthetix's third ecosystem integration action in the past six months, following the acquisitions of Kwenta and TLX. Synthetix founder Kain Warwick stated that this integration will simplify protocol architecture and governance, driving the development of the derivatives platform.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
